[go: up one dir, main page]

US20060035924A1 - Daily melatonin dosing units - Google Patents

Daily melatonin dosing units Download PDF

Info

Publication number
US20060035924A1
US20060035924A1 US10/533,517 US53351705A US2006035924A1 US 20060035924 A1 US20060035924 A1 US 20060035924A1 US 53351705 A US53351705 A US 53351705A US 2006035924 A1 US2006035924 A1 US 2006035924A1
Authority
US
United States
Prior art keywords
container
melatonin
agent
derivative
arrangement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/533,517
Other languages
English (en)
Inventor
Hans Schmid
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ASAT AG Applied Science and Technology
Original Assignee
ASAT AG Applied Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32233793&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20060035924(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE10250646A external-priority patent/DE10250646A1/de
Priority claimed from DE20217814U external-priority patent/DE20217814U1/de
Application filed by ASAT AG Applied Science and Technology filed Critical ASAT AG Applied Science and Technology
Priority to US10/533,517 priority Critical patent/US20060035924A1/en
Assigned to ASAT AG APPLIED SCIENCE & TECHNOLOGY reassignment ASAT AG APPLIED SCIENCE & TECHNOLOGY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SCHMID, HANS W.
Publication of US20060035924A1 publication Critical patent/US20060035924A1/en
Priority to US12/116,484 priority patent/US8017645B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/06—Ampoules or carpules
    • A61J1/067—Flexible ampoules, the contents of which are expelled by squeezing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/046—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/068—Microemulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/673—Vitamin B group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9771—Ginkgophyta, e.g. Ginkgoaceae [Ginkgo family]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00—Devices for applying media, e.g. remedies, on the human body
    • A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/87—Application Devices; Containers; Packaging

Definitions

  • the present invention relates to a disposable container for a medicament or cosmetic agent for topical application, containing a single dose of melatonin or of a melatonin derivative which corresponds to a locally effective dose but which does not cause any systemic effect.
  • Melatonin-containing agents can be used for various medical and cosmetic purposes.
  • the document DE 101 10 418.9 discloses melatonin-containing compositions for topical application on the skin and in the hair.
  • the subject of the present invention is a disposable container for a medicament or cosmetic agent for topical application, containing a single dose of melatonin or of a melatonin derivative which corresponds to a locally effective dose but which does not cause any systemic effect.
  • the disposable container according to the invention permits application of a dose of melatonin or of a melatonin derivative which is locally effective but which causes no undesired change in the normal melatonin plasma level.
  • the single dose of melatonin or of melatonin derivative which is applied according to the invention causes no significant elevation of the melatonin plasma level for example.
  • melatonin or melatonin derivative includes melatonin and/or melatonin derivatives and salts, esters or complexes thereof.
  • Preferred melatonin derivatives include, for example, 5-methoxytryptamine, 5-methoxytryptophan, 5-methoxytryptophol, 5-methoxy-indole-3-acetic acid and 6-hydroxymelatonin.
  • the single dose according to the invention represents a dose which permits a positive cosmetic and/or therapeutic effect without significant changes in the plasma level.
  • a single dose of from approximately 0.001 to approximately 1.0 mg of melatonin is preferred, and more preferably a single dose of from approximately 0.01 to approximately 0.2 mg of melatonin.
  • a single dose can be applied once or several times daily.
  • the single dose corresponds to a daily dose, particularly preferably a daily dose to be used in the evenings.
  • the medicament or cosmetic agent is preferably present as a liquid formulation.
  • suitable formulations for topical application of the agent are solutions, suspensions, emulsions, microemulsions, nanosystems, creams, gels, lotions, sprays, foams or ointments, and any other formulation which can be applied topically.
  • the agent is particularly preferably provided in the form of a cosmetic solution.
  • the medicament or cosmetic agent contained in the disposable container according to the invention can have different concentrations of melatonin or of a melatonin derivative.
  • the agent preferably contains a concentration of approximately 0.001 to approximately 0.01% (by weight), more preferably approximately 0.003 to 0.004% (by weight) of melatonin or of a melatonin derivative.
  • a particularly preferred concentration is approximately 0.0033% (by weight).
  • the therapeutic or cosmetic agent contains melatonin or a melatonin derivative as sole active substance.
  • the agent can, however, also contain one or more further active substances such as vitamin A, vitamin A acid or other vitamin A derivatives, biotin and/or gingko biloba.
  • the medicament or cosmetic agent contains a combination of the active substances melatonin or melatonin derivative with biotin and/or gingko biloba.
  • the active substances in this embodiment can be in different dosages.
  • a particularly preferred dosage of this combination is from approximately 0.05 to approximately 0.2 mg, particularly preferably approximately 0.1 mg of melatonin or melatonin derivative, from approximately 0.2 to approximately 0.4 mg, particularly preferably approximately 0.3 mg of biotin, and from approximately 1.3 to approximately 1.7 mg, particularly preferably approximately 1.5 mg of gingko biloba.
  • Gingko biloba can in this case be contained for example as an extract, in particular as a dry extract, and/or in the form of one or more ingredients.
  • the agent contains a combination of the active substances melatonin or melatonin derivative and vitamin A, vitamin A acid or another derivative of vitamin A.
  • the dosage of melatonin or melatonin derivative is preferably from approximately 0.05 to 0.2 mg, particularly preferably approximately 0.1 mg of melatonin.
  • the medicament or cosmetic agent can also contain one or more cosmetic and/or pharmaceutical auxiliaries or additives, for example thickeners, minerals or perfumes.
  • composition according to the invention can be used to promote hair growth, in particular to prevent and/or treat alopecia in men or in women.
  • Particularly preferred indications are male pattern androgenetic alopecia, female pattern androgenetic alopecia, male pattern diffuse alopecia and female pattern diffuse alopecia.
  • the disposable container according to the invention can contain different volumes of the medicament or cosmetic agent.
  • the disposable container contains approximately 2.5 to approximately 3.5 ml, preferably approximately 2.9 to approximately 3.2 ml of the agent.
  • a particularly preferred volume is approximately 3.0 ml.
  • the therapeutic or cosmetic agent can be filled into the container using any suitable method known in the prior art.
  • the agent is preferably filled into the container under GMP conditions. In this way it is possible to ensure that the agent is sterile and that, when the agent is applied, no problems arise in respect of bacterial contamination.
  • the disposable container according to the invention can in principle be made of any desired material, in particular a material approved for packaging of food products and pharmaceutical products.
  • suitable materials are plastics and mixtures of plastics.
  • particularly suitable plastics are polyethylene, polyvinyl chloride, polystyrene, polypropylene, polycycloolefins or mixtures or copolymers thereof, with particular preference being given to polyethylene or polycycloolefins.
  • the disposable container can be transparent, non-transparent, colorless or colored. Any desired dyes can for example be added to the plastic in order to obtain a colored container.
  • a non-transparent container is preferred for use if the agent contains light-sensitive substances, because a non-transparent container additionally affords protection from light.
  • the disposable container according to the invention can in principle have any desired shape. Examples of preferred containers are shown in FIGS. 1 and 2 .
  • a suitable disposable container preferably comprises a part in which the agent is contained, and a disposable closure piece which is connected to the lower part via a predetermined break line.
  • Simple and safe handling of the container is advantageously ensured by the fact that it preferably has, on its head, a disposable closure piece which is opened by turning it.
  • the container can thus be easily opened.
  • the agent can emerge only if pressure is applied. This pressure can for example be exerted by hand during the application. This property allows the user to correctly dose the agent and position it in a targeted manner. If the agent is to be applied to the scalp or hair, the opened container can be guided directly through the hair like a comb. This permits straightforward and safe handling of the container and correct dosing of the agent.
  • the disposable container carries lettering either printed on or embossed and/or is provided with a label.
  • Two or more disposable containers can furthermore be connected to one another in a detachable manner.
  • 5 or 10 containers are preferably connected to one another and form an arrangement.
  • a container or an arrangement of containers can also be packed, preferably in a lightproof package, particularly preferably in an aluminum bag for example.
  • aluminum bag includes bags made of aluminum and also bags which for example are coated with aluminum on the outside or inside.
  • bags made of one or more layers of plastic and/or paper can be coated with aluminum.
  • a preferred bag comprises, for example, an aluminum-containing laminated foil which additionally includes polyethylene, polyester and/or paper.
  • a package in particular a lightproof package, permits storage over a fairly long period of time without loss of efficacy of the agent. Furthermore, such a package can provide protection against gas loss.
  • an aluminum bag in which one or more disposable containers are packed can be printed on and/or provided with a label.
  • a package unit comprising several arrangements of disposable containers is provided.
  • FIGS. 1 and 2 The invention is further explained by attached FIGS. 1 and 2 and examples.
  • FIG. 1 shows an arrangement of 5 disposable containers connected to one another in a detachable manner and in a preferred configuration.
  • 1 A shows a front view, 1 B a plan view, 1 C a side view, and 1 D a perspective view obliquely from above.
  • FIG. 2A shows a front view of an individual disposable container in a preferred configuration.
  • 2 B shows a front view of an arrangement of 10 disposable containers connected to one another in a detachable manner
  • 2 C shows a side view
  • 2 D shows a plan view of said arrangement.
  • the composition contains 0.05% by weight of gingko biloba dry extract, 0.01% by weight of biotin, 0.0033% by weight of melatonin and other additives, water, and ethanol.
  • the pH of the composition is between 3.5 and 4.
  • Example 1 The composition described in Example 1 was tested on 8 healthy female patients in a randomized double-blind study with placebo control and a crossover design.
  • the daily dose was 0.1 mg of melatonin (3 ml of the composition) which was applied to the scalp each day before bedtime, for a period of 14 days.
  • Urine and blood samples were taken from the patients and were assayed for melatonin and the metabolite 6-hydroxymelatonin sulfate.
  • compositions for 14 days did not increase the plasma concentration of melatonin, or the concentration of 6-hydroxymelatonin sulfate in urine, above physiological concentrations.
  • Topical application of the melatonin-containing composition was not associated with side effects. Nor were any effects found on reaction times or on cortical excitation parameters.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Medical Informatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Packages (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
US10/533,517 2002-10-30 2003-10-30 Daily melatonin dosing units Abandoned US20060035924A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/533,517 US20060035924A1 (en) 2002-10-30 2003-10-30 Daily melatonin dosing units
US12/116,484 US8017645B2 (en) 2002-10-30 2008-05-07 Melatonin daily dosage units

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
DE10250646A DE10250646A1 (de) 2002-10-30 2002-10-30 Melatonin in kosmetischen Formulierungen
DE10250646.9 2002-10-30
DE20217814.5 2002-11-18
DE20217814U DE20217814U1 (de) 2002-11-18 2002-11-18 Melatonin-Tagesdosierungseinheiten
US10/353,056 2003-01-29
US10/353,056 US20040094449A1 (en) 2002-11-18 2003-01-29 Melatonin daily dosage units
PCT/EP2003/012099 WO2004039369A1 (fr) 2002-10-30 2003-10-30 Unite d'administration quotidienne d'une dose de melatonine
US10/533,517 US20060035924A1 (en) 2002-10-30 2003-10-30 Daily melatonin dosing units

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/353,056 Continuation-In-Part US20040094449A1 (en) 2002-10-30 2003-01-29 Melatonin daily dosage units

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/116,484 Continuation US8017645B2 (en) 2002-10-30 2008-05-07 Melatonin daily dosage units

Publications (1)

Publication Number Publication Date
US20060035924A1 true US20060035924A1 (en) 2006-02-16

Family

ID=32233793

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/533,517 Abandoned US20060035924A1 (en) 2002-10-30 2003-10-30 Daily melatonin dosing units
US10/533,516 Active 2027-10-30 US8062648B2 (en) 2002-10-30 2003-10-30 Formulations containing melatonin, ginkgo biloba, and biotin
US12/116,484 Expired - Lifetime US8017645B2 (en) 2002-10-30 2008-05-07 Melatonin daily dosage units

Family Applications After (2)

Application Number Title Priority Date Filing Date
US10/533,516 Active 2027-10-30 US8062648B2 (en) 2002-10-30 2003-10-30 Formulations containing melatonin, ginkgo biloba, and biotin
US12/116,484 Expired - Lifetime US8017645B2 (en) 2002-10-30 2008-05-07 Melatonin daily dosage units

Country Status (21)

Country Link
US (3) US20060035924A1 (fr)
EP (2) EP1569724B1 (fr)
JP (2) JP2006510556A (fr)
KR (2) KR20050083836A (fr)
CN (2) CN1708331A (fr)
AT (1) ATE419038T1 (fr)
AU (2) AU2003278164A1 (fr)
BR (2) BR0315878A (fr)
CA (2) CA2504361A1 (fr)
DE (1) DE50311024D1 (fr)
DK (1) DK1569724T3 (fr)
EC (2) ECSP055820A (fr)
ES (1) ES2315541T3 (fr)
HR (2) HRP20050386A2 (fr)
IS (1) IS7820A (fr)
MX (2) MXPA05004537A (fr)
NO (2) NO334680B1 (fr)
NZ (2) NZ539871A (fr)
PL (2) PL224878B1 (fr)
SI (1) SI1569724T1 (fr)
WO (2) WO2004039369A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008148015A1 (fr) * 2007-05-24 2008-12-04 The Trustees Of Columbia University In The City Of New York Formulation de mélatonine à libération prolongée
US20100124561A1 (en) * 2008-11-18 2010-05-20 Studin Joel R Anti-Aging Product
US20110130372A1 (en) * 2008-07-29 2011-06-02 Gaetano Agostinacchio Composition comprising estrone and hydrocortisone for use in the topical treatment of baldness
US20200179223A1 (en) * 2018-12-05 2020-06-11 The Procter & Gamble Company Container For Personal Health Compositions
WO2025078561A1 (fr) * 2023-10-11 2025-04-17 Santen Sas Kit pour stabiliser des émulsions de prostaglandine
US12291635B2 (en) 2018-12-05 2025-05-06 Avient Corporation Composition for protecting light sensitive materials

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101128208A (zh) 2004-12-24 2008-02-20 都菲斯特股份有限公司 毛发学制剂和毛发学治疗
GB0513581D0 (en) 2005-07-01 2005-08-10 Norton Healthcare Ltd Container
ITGE20070009A1 (it) * 2007-01-24 2008-07-25 Leila Baeram Composizione cosmetica e metodo per favorire la ricrescita dei capelli.
US8940326B2 (en) 2007-03-19 2015-01-27 Vita Sciences Llc Transdermal patch and method for delivery of vitamin B12
IT1401173B1 (it) * 2010-07-26 2013-07-12 Lameplast Spa Contenitore richiudibile per prodotti fluidi, particolarmente per prodotti medicali, farmaceutici e cosmetici
PL3062797T3 (pl) 2014-05-23 2020-08-24 Triple Hair Inc. Kompozycje zmniejszające wypadanie włosów i/lub zwiększające odrastanie włosów
US11696883B2 (en) 2014-05-23 2023-07-11 Triple Hair Inc. Compositions for reducing hair loss and/or increasing hair regrowth
CN107205908B (zh) * 2015-01-30 2020-03-10 现代药品株式会社 稳定性得到改善的含褪黑激素的育发、养发或生发促进用组合物
US10342735B2 (en) * 2015-06-11 2019-07-09 Tokitae Llc Multi-monodose containers
US20160361232A1 (en) * 2015-06-11 2016-12-15 Tokitae Llc Packaging Multi-Monodose Containers
PT3347009T (pt) 2015-07-08 2022-01-12 Triple Hair Inc Composição compreendendo resveratrol e melatonina para reduzir a perda de cabelo e/ou aumentar o crescimento do cabelo
WO2017021247A1 (fr) * 2015-07-31 2017-02-09 Isdin, S.A. Lotion anti-chute des cheveux
TWI706898B (zh) * 2015-12-09 2020-10-11 美商脫其泰有限責任公司 包裝能折疊容器的方法
KR102142228B1 (ko) * 2019-12-19 2020-08-06 홍용익 초유, 비오틴 및 과라나 추출물을 함유하는 탈모 방지 및 발모 촉진 효능을 갖는 조성물 및 그의 제조방법
KR102644461B1 (ko) * 2023-08-01 2024-03-12 (주)지에프씨생명과학 경피흡수율이 우수한 모발 성장 촉진용 리포좀 조성물

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4654361A (en) * 1986-01-27 1987-03-31 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Method of lowering intraocular pressure using melatonin
US4746674A (en) * 1985-08-27 1988-05-24 Cellena (Cell Engineering) Ag Melatonin compositions and uses thereof
US5006004A (en) * 1987-11-25 1991-04-09 The Proctor & Gamble Company Topical applicator for liquid
US5577636A (en) * 1994-06-10 1996-11-26 Yoshida Kogyo Co., Ltd. Multi-tube container having breakable connections at both ends thereof
US5952373A (en) * 1994-12-13 1999-09-14 Beiersdorf Ag Agents acting against hyperreactive and hypoactive, deficient skin conditions and manifest dermatitides
US5985293A (en) * 1996-07-25 1999-11-16 Societe L'oreal S.A. Antioxidative dermocosmetic compositions comprising very low dosages of melatonin/analogs
US6281241B1 (en) * 1999-11-30 2001-08-28 Asat Ag Applied Science And Technology Use of melatonin for the treatment of androgenetic alopecia
US20010031744A1 (en) * 1997-02-04 2001-10-18 Kosbab John V. Compositions and methods for prevention and treatment of chronic diseases and disorders including the complications of diabetes mellitus
US20050271692A1 (en) * 2002-06-25 2005-12-08 Cosmeceutic Solutions Pty. Ltd. Topical cosmetic compositions

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE7834570U1 (de) 1978-11-21 1979-03-22 Richardson Merrell Gmbh Mehrfachpackung
GB2079238B (en) 1980-05-12 1984-09-05 Glaxo Group Ltd Plastics medicament containers
DK154993C (da) 1984-01-17 1989-05-29 Pharmacia As Beholdersaet bestaaende af et antal til engangsbrug beregnede, tubeformede beholdere, der er indbyrdes forbundet
US4818540A (en) 1985-02-25 1989-04-04 Rutgers, The State University Of New Jersey Transdermal fertility control system and process
JPS61212512A (ja) * 1985-03-19 1986-09-20 Shiseido Co Ltd 養毛料
US4651361A (en) * 1985-10-07 1987-03-24 Nolan William D Portable combination hair shampoo basin and drying hood
JPH01242516A (ja) * 1988-03-24 1989-09-27 Z Lederman Hull 養毛剤、養毛シャンプー及び養毛促進剤
JP2835970B2 (ja) * 1989-11-20 1998-12-14 株式会社コーセー 養毛料
JP2636118B2 (ja) * 1991-09-10 1997-07-30 三省製薬株式会社 育毛剤
US5750107A (en) * 1993-02-12 1998-05-12 Nomura; Manabu Hair growth promoter
JPH0853327A (ja) * 1994-06-10 1996-02-27 Toshihiro Matsumoto アラントインまたはその誘導体による養毛・育毛剤
US5702691A (en) † 1994-12-02 1997-12-30 Kao Corporation Flavanonol derivatives and hair-nourishing, hair growing compositions containing the derivatives
DE19509354A1 (de) * 1994-12-08 1996-06-13 Klett Loch Lore M Kombinationspräparat zur Förderung des Haarwachstums und ggf. des Haut- und Nagelwachstums sowie zur Verhinderung bzw. zur Beseitigung von Haarausfall
CN2223996Y (zh) 1995-07-26 1996-04-10 沈言华 清洁灌肠器
US6602526B2 (en) 1996-02-23 2003-08-05 Medical Doctors Research Institute Oral compositions containing lotus
EP0867181A1 (fr) * 1997-03-26 1998-09-30 Franciscus Wilhelmus Henricus Maria Merkus Composition nasale de mélatonine
AU750361B2 (en) 1997-03-26 2002-07-18 Franciscus W.H.M. Merkus Nasal melatonin composition
JPH10283531A (ja) * 1997-03-31 1998-10-23 Toshiba Corp 現金処理システム
JPH10287531A (ja) * 1997-04-14 1998-10-27 Kose Corp 毛髪用化粧料
JPH11180833A (ja) * 1997-12-16 1999-07-06 Shiseido Co Ltd 頭皮頭髪用組成物
US6030948A (en) † 1997-12-19 2000-02-29 Mann; Morris A. Hair regeneration compositions for treatment of alopecia and methods of application related thereto
US6524619B2 (en) 2000-01-27 2003-02-25 Chronorx, Inc. Dosage forms useful for modifying conditions and functions associated with hearing loss and/or tinnitus
US6596266B2 (en) * 2000-02-18 2003-07-22 Natural Science, Inc. Compositions containing minoxidil and saw palmetto for treating baldness
DE10035735C2 (de) * 2000-07-22 2003-02-20 Wella Ag Haartonikum zur Vorbeugung oder Behandlung von Haarausfall
JP2002050328A (ja) * 2000-08-02 2002-02-15 Seiko Instruments Inc 非水電解質二次電池
GB0019327D0 (en) * 2000-08-08 2000-09-27 Buchanan Baillie Hamilton Paul Slimming system
DE20019365U1 (de) 2000-11-15 2001-01-18 Dr. Gerhard Mann Chem.-pharm. Fabrik GmbH, 13581 Berlin Eindosis-Kunststoffbehältnis zur Aufnahme von einem flüssigen oder gelartigen pharmazeutischen Präparat
DE10110418A1 (de) 2001-03-05 2002-09-12 Asat Ag Applied Science & Tech Melatonin-Vitamin-A-Präparate
US6964969B2 (en) * 2001-04-19 2005-11-15 Mccleary Edward Larry Composition and method for treating impaired or deteriorating neurological function
WO2003049687A2 (fr) * 2001-12-06 2003-06-19 Weller Health, Inc. Compositions medicinales et methodes therapeutiques
US6956266B1 (en) * 2004-09-09 2005-10-18 International Business Machines Corporation Structure and method for latchup suppression utilizing trench and masked sub-collector implantation

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4746674A (en) * 1985-08-27 1988-05-24 Cellena (Cell Engineering) Ag Melatonin compositions and uses thereof
US4654361A (en) * 1986-01-27 1987-03-31 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Method of lowering intraocular pressure using melatonin
US5006004A (en) * 1987-11-25 1991-04-09 The Proctor & Gamble Company Topical applicator for liquid
US5577636A (en) * 1994-06-10 1996-11-26 Yoshida Kogyo Co., Ltd. Multi-tube container having breakable connections at both ends thereof
US5952373A (en) * 1994-12-13 1999-09-14 Beiersdorf Ag Agents acting against hyperreactive and hypoactive, deficient skin conditions and manifest dermatitides
US5985293A (en) * 1996-07-25 1999-11-16 Societe L'oreal S.A. Antioxidative dermocosmetic compositions comprising very low dosages of melatonin/analogs
US20010031744A1 (en) * 1997-02-04 2001-10-18 Kosbab John V. Compositions and methods for prevention and treatment of chronic diseases and disorders including the complications of diabetes mellitus
US6281241B1 (en) * 1999-11-30 2001-08-28 Asat Ag Applied Science And Technology Use of melatonin for the treatment of androgenetic alopecia
US20050271692A1 (en) * 2002-06-25 2005-12-08 Cosmeceutic Solutions Pty. Ltd. Topical cosmetic compositions

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008148015A1 (fr) * 2007-05-24 2008-12-04 The Trustees Of Columbia University In The City Of New York Formulation de mélatonine à libération prolongée
US20100120887A1 (en) * 2007-05-24 2010-05-13 The Trustees Of Columbia University In The City Of New York Sustained release formulation of melatonin
US20110130372A1 (en) * 2008-07-29 2011-06-02 Gaetano Agostinacchio Composition comprising estrone and hydrocortisone for use in the topical treatment of baldness
US20100124561A1 (en) * 2008-11-18 2010-05-20 Studin Joel R Anti-Aging Product
WO2010059547A3 (fr) * 2008-11-18 2010-10-07 Studin Joel R Produit anti-vieillissement
US9393182B2 (en) 2008-11-18 2016-07-19 Scarguard Labs, Llc Anti-aging product
US20200179223A1 (en) * 2018-12-05 2020-06-11 The Procter & Gamble Company Container For Personal Health Compositions
US11877981B2 (en) * 2018-12-05 2024-01-23 The Procter & Gamble Company Container for personal health compositions
US12291635B2 (en) 2018-12-05 2025-05-06 Avient Corporation Composition for protecting light sensitive materials
WO2025078561A1 (fr) * 2023-10-11 2025-04-17 Santen Sas Kit pour stabiliser des émulsions de prostaglandine

Also Published As

Publication number Publication date
NO20052490L (no) 2005-05-24
WO2004039369A1 (fr) 2004-05-13
ECSP055820A (es) 2005-08-11
CN1708331A (zh) 2005-12-14
IS7820A (is) 2005-04-25
PL376226A1 (en) 2005-12-27
HRP20050386A2 (en) 2006-06-30
US8062648B2 (en) 2011-11-22
CA2504341A1 (fr) 2004-05-13
DK1569724T3 (da) 2009-03-30
US20080293803A1 (en) 2008-11-27
AU2003278164A1 (en) 2004-05-25
KR20050083836A (ko) 2005-08-26
EP1569724B1 (fr) 2008-12-31
PL375507A1 (en) 2005-11-28
EP1562585B1 (fr) 2010-11-24
NO20052494L (no) 2005-05-24
EP1562585B2 (fr) 2017-05-24
WO2004039454A1 (fr) 2004-05-13
EP1569724A1 (fr) 2005-09-07
ES2315541T3 (es) 2009-04-01
CN1708301A (zh) 2005-12-14
NO335547B1 (no) 2014-12-29
NO20052490D0 (no) 2005-05-24
BR0315878A (pt) 2005-10-04
ATE419038T1 (de) 2009-01-15
ECSP055819A (es) 2005-08-11
HRP20050385A2 (en) 2006-06-30
DE50311024D1 (de) 2009-02-12
JP2006510556A (ja) 2006-03-30
AU2003283327A1 (en) 2004-05-25
NO334680B1 (no) 2014-05-12
KR100849916B1 (ko) 2008-08-04
SI1569724T1 (sl) 2009-04-30
US8017645B2 (en) 2011-09-13
KR20050055789A (ko) 2005-06-13
MXPA05004535A (es) 2005-11-23
EP1562585A1 (fr) 2005-08-17
NZ539871A (en) 2008-06-30
BR0315927A (pt) 2005-09-20
CA2504361A1 (fr) 2004-05-13
JP2006513255A (ja) 2006-04-20
NZ539872A (en) 2007-04-27
PL212984B1 (pl) 2012-12-31
MXPA05004537A (es) 2005-11-23
PL224878B1 (pl) 2017-02-28
NO20052494D0 (no) 2005-05-24
US20060099278A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
US8017645B2 (en) Melatonin daily dosage units
US5196001A (en) Devices and methods for preparing pharmaceutical solutions
HUP0600765A2 (en) Container for stable carbondioxide foam, process for producing stable carbondioxide foam and method for using of foam
BRPI1010958B1 (pt) acondicionamento termoformado, sua utilização e seu método de fabricação
US10251822B2 (en) Methods and compositions for treating cutaneous fungal infections
IL168287A (en) Disposable medicament/cosmetic container for topical application and arrangements and package units comprising the same
US20040094449A1 (en) Melatonin daily dosage units
US20080073350A1 (en) Assemblies for dispensing material, systems and kits including the assemblies, and methods of using and forming same
ES2353865T3 (es) Unidades de dosificación diaria de melatonina.
US20060182790A1 (en) Dermal medicaments application enhancer
US20020025917A1 (en) Compartmentalized device to enable a process of liquefying and administering aspirin as a first aid to heart attack victims
HK1074793B (en) Daily melatonin dosing units
US20100124561A1 (en) Anti-Aging Product
RU12528U1 (ru) Устройство для хранения и нанесения лекарственных и косметических средств
ES2389373T3 (es) Disposición de aplicación para medicamentos que van a aplicarse sobre la piel y uso de un envase como disposición de aplicación
KR950006561Y1 (ko) 일회용 의약품 및 위생용품이 구비된 구급약품
Nahornyi et al. Development of technology and research of gel with pentoxifylline
SK500592021U1 (sk) Súprava obsahujúca biologicky aktívny prípravok
KR920700041A (ko) 치료화합물과 그의 조성 및 용도
KR20070020421A (ko) 각질 조직의 처리
TH23425A (th) สารสูตรผสมยาแอโรโซล
CZ6245U1 (cs) Dávkovač léků

Legal Events

Date Code Title Description
AS Assignment

Owner name: ASAT AG APPLIED SCIENCE & TECHNOLOGY, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SCHMID, HANS W.;REEL/FRAME:016645/0421

Effective date: 20050606

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION